{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Urine samples were planned to be collected from participants in the pharmacokinetic/pharmacodynamic expansion cohort for analysis of GSK2816126 and its metabolites. Samples were not collected due to early termination of the study; therefore, no analysis could be performed.","groups":[{"description":"At maximum tolerated or recommended phase II dose, participants with GCB-DLBCL were enrolled in Part 1 expansion cohorts and received GSK2816126 twice-weekly, as intravenous solution.","id":"OG000","title":"Part 1: Participants With GCB-DLBCL"},{"description":"At maximum tolerated or recommended phase II dose, participants with solid tumors were enrolled in Part 1 expansion cohorts and received GSK2816126 twice-weekly, as intravenous solution.","id":"OG001","title":"Part 1: Participants With Solid Tumors"}],"populationDescription":"Pharmacokinetic Population. Samples were not collected due to early study termination.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 0 to 24 hours post-dose on Day 1; 0 to 8 hours post-dose on Day 15","title":"Part 1: Concentration of GSK2816126 and Its Metabolites in Urine","type":"SECONDARY"}